The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Gastric Cancer MORE >>

According to a presentation at the 2018 ESMO Congress, risk of death was reduced with trifluridine/tipiracil versus placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer. Lead TAGS trial author Hendrik-Tobias Arkenau, MD, PhD, said there was also improvement in progression-free survival and disease control.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.